Sign In
Buy NBTX
$38.39
-1.77 (-4.41%)
At Close: Jul 31, 2026
7 Biotech Stocks With Key Catalysts for May
06:35am, Wednesday, 11'th May 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript
10:50am, Thursday, 31'st Mar 2022
Nanobiotix S.A (NBTX) CEO Laurent Levy on Q4 2021 Results - Earnings Call Transcript
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
04:15pm, Wednesday, 16'th Mar 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX TO ANNOUNCE FULL YEAR 2021 FINANCIAL RESULTS ON MARCH 30, 2022.
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
04:15pm, Tuesday, 04'th Jan 2022
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based a
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based a
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanophysics
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
04:15pm, Wednesday, 08'th Sep 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-base
Nanobiotix Provides Second Quarter Operational and Financial Update
04:15pm, Tuesday, 20'th Jul 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Nanobiotix (Euronext: NANO – NASDAQ: NBTX) provides second quarter operational and financial update.
Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients
06:39am, Thursday, 01'st Jul 2021
Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation. The
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
04:15pm, Monday, 07'th Jun 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical sta
Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
09:34am, Friday, 04'th Jun 2021
Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneerin
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
04:15pm, Tuesday, 25'th May 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pi
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: Please replace the release dated May 19, 2021 with the following corrected version due to multiple revisions. NANOBIOTIX ANN
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pionee
